Event Details

AHA 2026 Oral Presentations

Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT
Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies
Title: First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia (ARO-DIMER-PA)
Presenter: Luke Laffin

Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT
Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies
Title: Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction with Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of SHASTA-3 and SHASTA-4
Presenter: Christie Ballantyne

Moderated Poster Sessions

Date & Time: Saturday, November 7, 9:15 am CT
Session Title: PL.MDP.01: Transforming Lipid Care Across the Lifespan
Topic: Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: 3-Year Data from the PALISADE Study and the Open-Label Extension
Presenter: Robert Rosenson

Date & Time: Saturday, November 7, 1:45 pm CT
Session Title: PL.MDP.01: Innovations in Lipid Science: Emerging Therapies and Population Impact
Topic: Impact of GLP-1 Receptor Agonist Use on Triglyceride Reduction with Plozasiran, PL.MDP.05: Innovations in Lipid Science: Emerging Therapies and Population Impact
Presenter: Daniel Gaudet